NHD Global
Reproductive & Hormone · Source-reviewed dossier
Source-Reviewed Research Dossier
hMG is a hormone preparation providing FSH and LH activity. These signals are involved in ovarian follicle development and reproductive hormone production. Follicles are the structures in which eggs develop. Human research has compared specific finished products, routes and combination protocols under medical monitoring. Follicle stimulation, ovulation and pregnancy are different outcomes, so stronger stimulation is not automatically better. Those clinical findings cannot be directly applied to NHD research material or used to predict pregnancy outcomes.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A 2025 randomized trial evaluated hMG-related stimulation outcomes in a defined patient population.
Protocol outcomes cannot be applied to an unapproved or differently standardized product.
Read the primary studyA controlled study compared administration within an assisted-reproduction setting.
The result is route-, dose- and finished-product-specific.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Protein or hormone research material · 75 IU/vial nominal · 10-vial pack · identity and release tests controlled by lot specification.
Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.
A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Protocol outcomes cannot be applied to an unapproved or differently standardized product.
View primary recordThe result is route-, dose- and finished-product-specific.
View primary recordThird-party publications selected for direct relevance.
Clinical trial. 2025. PMID 40193016.
Clinical study. 2000. PMID 10871458.
Concise answers for researchers comparing identity, evidence and catalog variants.
hMG supplies follicle-stimulating hormone and luteinizing hormone activity, which together encourage egg-containing follicles to grow and mature. In the human studies summarized, it was used within monitored fertility protocols. One comparison found that under-the-skin injection worked about as well as into-muscle injection. Another found that combining it with a lower dose of letrozole was at least as good as a higher dose. These findings apply only to the specific regulated products and protocols, not to any laboratory catalog material.
The human results come from named, regulated fertility products given at specific doses under clinical monitoring. They cannot be applied to a research research material, an unapproved preparation, or a differently standardized mixture. Catalog identity, potency and purity are defined by the product specification and lot documents, not by clinical trial results. Catalog material is for laboratory research, development and manufacturing use only.
Human clinical evidence exists for assisted-reproduction protocols, but product comparability requires potency and impurity controls.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
Menotropins trials evaluate named, standardized fertility medicines within monitored protocols. Their outcomes cannot be transferred to an undefined hMG mixture or reduced to a…
Updated October 1, 2026
Human menopausal gonadotropin is a biological mixture standardized by FSH and LH activity, not a single compound with one molecular formula.
Updated October 1, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: G75 · 75 IU × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
